Biotech Values

[DewDiligence]

> COR – why do you think Cortex doing a financing has hurt the credibility of the company?<

It’s not the financing per se that has hurt credibility, but rather what the financing suggests: that interest from Big Pharma may not be all it’s been cracked up to be.

>why would you think there's a possibility of no interest in CX717 for ADHD?<

Are you saying this thought has not even entered your mind?

As you know, I’ve long thought the CX-717 results in ADHD were modest, that a new drug with Strattera-like efficacy was apt to be a commercial dud, and that COR’s main underlying value was in the high-impact realm. The latest financing does not prove I was right, but it doesn’t prove I was wrong, either. Regards, Dew